SOUTH SAN FRANCISCO, Calif. , Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy , D.Phil ., president, chief executive officer, and chairman, will present at the B.

- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to determine next steps for program in 2023 - - CytomX and Moderna announce today, separately, a strategic

Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody ® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments SOUTH SAN